- Describe the use of PD-L1 gene alterations as a surrogate genetic biomarker for an immune inflamed environment in DLBCL and in predicting response to PD-1 blockade therapy in relapsed/refractory DLBCL patients.
- Describe how recently-acquired large genomic datasets will be interrogated to identify DLBCL clusters associated with unique immune signatures.
- Describe the use of a genome-wide CRISPR/Cas9 screen to identify lymphoma-intrinsic molecules that regulate phagocytosis by macrophages in the context of CD47-SIRP-alpha axis blockade.
Monday, April 1, 2019 - 12:00pm to 1:00pm
Justin W. Kline, MD; James Godfrey, MD; Michael J. Leukam, MD, MS
5841 South Maryland AvenueMC2115 HemOnc Conference Room E215
Chicago, IL 60637
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation